Benicar Sales Data
| Rank 85 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Benicar U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 85 ( 2) |
$203,336 | 3.22% | 1,355 | -4.10% |
| Q3 2013 | 87 ( 11) |
$196,986 | -3.74% | 1,413 | -5.42% |
| Q2 2013 | 76 (3) |
$204,630 | -0.04% | 1,494 | -0.33% |
| Q1 2013 | 79 (7) |
$204,717 | 5.92% | 1,499 | -0.27% |
| Q4 2012 | 86 | $193,275 | 2.27% | 1,503 | 2.31% |
| Q3 2012 | 86 (7) |
$188,980 | 9.67% | 1,469 | 1.38% |
| Q2 2012 | 93 (1) |
$172,324 | -1.31% | 1,449 | -1.76% |
| Q1 2012 | 94 | $174,619 | 2.79% | 1,475 | -1.60% |
| Q4 2011 | 94 (1) |
$169,877 | 4.87% | 1,499 | -0.86% |
| Q3 2011 | 93 (1) |
$161,995 | -5.94% | 1,512 | -5.85% |
| Q2 2011 | 92 (2) |
$172,226 | -1.37% | 1,606 | -2.96% |
| Q1 2011 | 94 | $174,621 | n/a | 1,655 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
